Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illinois Tool Works Inc. (ITW) vs Novavax Inc (NVAX) Price & Performance

Illinois Tool Works Inc.Trade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Illinois Tool Works Inc. vs Novavax Inc — how do they compare? Illinois Tool Works Inc. trades at $263.78 (market cap $74.38B), while Novavax Inc trades at $12.83 (market cap $1.82B). The key difference: Illinois Tool Works Inc. is far larger — about 40.9× Novavax Inc's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Novavax Inc for 59 Days on average.

ITWNVAX
Market Cap
$74.38B$1.82B
Volume
1,125,4776,198,505
Sector
IndustrialsHealth
52-Week High
$299.60$12.56
52-Week Low
$241.07$6.22
Typical Hold Time
67 Days59 Days
Enterprise Value
$83.23B$1.39B
Dividend Yield
2.63%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illinois Tool Works Inc.

ITW trades at $264.42, up 1.25% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its 59-year dividend growth streak. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.

Outlook remains balanced with upside to $276.86 consensus target but technical weakness near-term. Key opportunities include dividend reliability and margin strength, while risks involve debt levels at 55.54% of assets and sector cyclicality. The stock offers quality exposure for dividend-growth investors despite current technical headwinds.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ITW
100% Buy0% Sell
Avg holding period · 67 Days
NVAX
55% Buy45% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Illinois Tool Works Inc.

Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.

Read more on ITW →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →